<?xml version="1.0" ?>
<GlossaryTerm id="CDR0000798300">
  <TermName>VAdriaC-IE</TermName>
  <TermPronunciation>(VAY-dree-ak …)</TermPronunciation>
  <TermDefinition>
    <DefinitionText>An abbreviation for a chemotherapy combination used to treat Ewing sarcoma and other sarcomas, such as mesenchymal chondrosarcoma. It includes the drugs vincristine sulfate, doxorubicin hydrochloride (Adriamycin), and cyclophosphamide, followed by ifosfamide and etoposide phosphate. Also called VAC-IE, VAC-IE regimen, and VAdriaC-IE regimen.</DefinitionText>
    <Dictionary>Cancer.gov</Dictionary>
    <Audience>Patient</Audience>
  </TermDefinition>
  <MediaLink ref="CDR0000798871" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;VAdriaC-IE&quot;" language="en" id="_3"/>
  <MediaLink ref="CDR0000798870" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;VAdriaC-IE&quot;" language="es" id="_4"/>
  <SpanishTermName>VAdriaC-IE</SpanishTermName>
  <SpanishTermDefinition>
    <DefinitionText>Nombre de una quimioterapia combinada que se usa para el tratamiento del sarcoma de Ewing y otros sarcomas, como el condrosarcoma mesenquimatoso. Incluye los medicamentos sulfato de vincristina,  clorhidrato de doxorrubicina (Adriamycin) y ciclofosfamida, seguidos de ifosfamida y fosfato de etopósido. También se llama régimen VAC-IE, régimen VAdriaC-IE y VAC-IE.</DefinitionText>
    <Dictionary>Cancer.gov</Dictionary>
    <Audience>Patient</Audience>
  </SpanishTermDefinition>
  <DateFirstPublished>2019-05-23</DateFirstPublished>
</GlossaryTerm>
